Single domain antibody and derivative proteins thereof against programmed death-ligand (PDL1)
US11225522B2 · kind B2 · utility
2Cited by
0References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 1, 2016 |
| Grant date | Jan 18, 2022 |
| Priority date | — |
| Expiry date | Aug 1, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the field of medical biology and discloses a single domain antibody and derivative proteins thereof against programmed death ligand (PDL1). In particular, the present invention discloses a programmed death ligand 1 (PDL1) binding molecule and the use thereof, especially the use for treating and/or preventing or diagnosing PDL1 relevant diseases such as tumor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.